Incyte INCY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ICLUSIG | $139.99M+4.4% | $134.07M+5.4% | $127.22M+6.6% | $119.39M+5.2% | $113.52M-0.7% | |
| JAKAFI | $3.14B+1.6% | $3.09B+1.8% | $3.04B+1.7% | $2.99B+2.0% | $2.93B+4.9% | |
| JAKAVI Royalty Revenues | $471.14M+2.9% | $457.73M+3.6% | $441.69M+2.3% | $431.79M+2.5% | $421.39M+0.6% | |
| Milestone and contract revenues | $167M+11.3% | $150M+200% | $50M+117% | $23M+27.8% | $18M-58.1% | |
| MINJUVI/MONJUVI | $164.25M+13.6% | $144.58M+6.7% | $135.48M+8.4% | $124.93M0.0% | $124.91M+4.8% | |
| NIKTIMVO | $193.11M+27.4% | $151.64M+58.6% | $95.6M+92.1% | $49.77M+266% | $13.61M— | |
| OPZELURA | $702.77M+3.6% | $678.46M+7.2% | $632.77M+8.3% | $584.08M+7.9% | $541.27M+6.5% | |
| Other product royalty revenues | $9.86M+25.1% | $7.88M+66.2% | $4.74M+43.7% | $3.3M+14.2% | $2.89M+33.1% | |
| PEMAZYRE | $90.83M+4.7% | $86.73M+0.2% | $86.52M+2.5% | $84.44M+2.3% | $82.51M+0.9% | |
| TABRECTA Royalty Revenues | $26.27M-1.6% | $26.7M+3.3% | $25.84M+2.3% | $25.26M+5.6% | $23.93M+5.2% | |
| ZYNYZ | $104.74M+57.8% | $66.35M+84.4% | $35.98M+157% | $14M+144% | $5.73M+79.8% | |
| Total revenues by Geography | ||||||
| Europe | $347.55M+7.4% | $323.73M-3.8% | $336.6M+11.2% | $302.76M+9.1% | $277.52M+6.6% | |
| Other countries | $23.62M+34.4% | $17.57M+25.5% | $14M+27.8% | $10.95M+41.4% | $7.75M+24.6% | |
| United States | $4.99B+4.0% | $4.8B+7.6% | $4.46B+4.5% | $4.27B+3.5% | $4.13B+3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Incyte break its business down?
- Incyte (INCY) reports total revenues by product across 12 parts — ICLUSIG, JAKAFI, JAKAVI Royalty Revenues, Milestone and contract revenues and MINJUVI/MONJUVI. Each is extracted from the segment footnotes and tracked over time.
- Where does Incyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Incyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
